Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

Davide Corti (), Siro Bianchi, Fabrizia Vanzetta, Andrea Minola, Laurent Perez, Gloria Agatic, Barbara Guarino, Chiara Silacci, Jessica Marcandalli, Benjamin J. Marsland, Antonio Piralla, Elena Percivalle, Federica Sallusto, Fausto Baldanti and Antonio Lanzavecchia ()
Additional contact information
Davide Corti: Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
Siro Bianchi: Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
Fabrizia Vanzetta: Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
Andrea Minola: Institute for Research in Biomedicine, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
Laurent Perez: Institute for Research in Biomedicine, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
Gloria Agatic: Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
Barbara Guarino: Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
Chiara Silacci: Institute for Research in Biomedicine, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
Jessica Marcandalli: Institute for Research in Biomedicine, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
Benjamin J. Marsland: University of Lausanne, Service de Pneumologie, CHUV, Rue du Bugnon 46, 1011 Lausanne, Switzerland
Antonio Piralla: Policlinico San Matteo, IRCCS, Piazzale Camillo Golgi 1, 27100 Pavia, Italy
Elena Percivalle: Policlinico San Matteo, IRCCS, Piazzale Camillo Golgi 1, 27100 Pavia, Italy
Federica Sallusto: Institute for Research in Biomedicine, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
Fausto Baldanti: Policlinico San Matteo, IRCCS, Piazzale Camillo Golgi 1, 27100 Pavia, Italy
Antonio Lanzavecchia: Institute for Research in Biomedicine, Università della Svizzera Italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland

Nature, 2013, vol. 501, issue 7467, 439-443

Abstract: A human monoclonal antibody has been identified which can cross-neutralize both human respiratory syncytial virus (HRSV) and human metapneumovirus (HMPV), demonstrating that a single monoclonal antibody can target different viruses, a discovery that may lead to the creation of new therapeutics and vaccines.

Date: 2013
References: Add references at CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
https://www.nature.com/articles/nature12442 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:501:y:2013:i:7467:d:10.1038_nature12442

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature12442

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().